Amneal Pharmaceuticals Inc - Class A risk profile
38 Normal where most of the sector sits
Measured 21 October 2026 from AMRX's filed statements. Recomputed nightly.
38 (Normal), driven by Leverage and coverage at 53, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 29 | Normal | Stable | One-year price volatility — 35.9% |
| Operating pressure | 22 | Normal | Easing | Costs outgrowing revenue — -0.8 percentage points |
| Cash conversion | 19 | Contained | Easing | Capital spending against operating cash — 0.21x |
| Leverage and coverage | 53 | Elevated | Easing | Interest cover — 2.50x |
| Competitive position | 52 | Elevated | Stable | R&D-intensity gap against peers — -11.7 percentage points |
| Concentration | 36 | Normal | Stable | Customer concentration — 1,334 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Amneal Pharmaceuticals Inc - Class A